Drug Profile
Research programme: RNAi-based hepatitis C therapy - Nucleonics
Latest Information Update: 20 Jan 2011
Price :
$50
*
At a glance
- Originator Nucleonics
- Class Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 26 Nov 2007 This programme is still in active development
- 09 Feb 2005 Nucleonics and Apath LLC have entered into a non-exclusive licensing agreement for Apath technology related to the 3' non-translated region of the hepatitis C viral genome
- 03 Dec 2003 Preclinical trials in Hepatitis C treatment in USA (IV)